Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

被引：0
|
作者：
Christopher M. Rubino
Nikolas J. Onufrak
Jakko van Ingen
David E. Griffith
Sujata M. Bhavnani
Dayton W. Yuen
Kevin C. Mange
Kevin L. Winthrop
机构：
[1] Institute for Clinical Pharmacodynamics,Department of Medical Microbiology, Radboudumc Center for Infectious Diseases
[2] Inc,undefined
[3] Radboud University Medical Center,undefined
[4] The University of Texas Health Science Center at Tyler,undefined
[5] National Jewish Health,undefined
[6] Insmed Incorporated,undefined
[7] Oregon Health and Science University,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2021年 / 46卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：277 / 287
页数：10
相关论文
共 50 条
  • [1] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
    Rubino, Christopher M.
    Onufrak, Nikolas J.
    van Ingen, Jakko
    Griffith, David E.
    Bhavnani, Sujata M.
    Yuen, Dayton W.
    Mange, Kevin C.
    Winthrop, Kevin L.
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (02) : 277 - 287
  • [2] Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
    Christopher M. Rubino
    Nikolas J. Onufrak
    Jakko van Ingen
    David E. Griffith
    Sujata M. Bhavnani
    Dayton W. Yuen
    Kevin C. Mange
    Kevin L. Winthrop
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46 : 573 - 574
  • [3] Pharmacokinetic (PK) Evaluation of Amikacin Liposome Inhalation Suspension (ALIS) in Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease
    Rubino, C. M.
    Onufrak, N.
    Griffith, D. E.
    Bhavnani, S. M.
    Eagle, G.
    Winthrop, K. L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [4] Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease (vol 46, pg 277, 2021)
    Rubino, Christopher M.
    Onufrak, Nikolas J.
    van Ingen, Jakko
    Griffith, David E.
    Bhavnani, Sujata M.
    Yuen, Dayton W.
    Mange, Kevin C.
    Winthrop, Kevin L.
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (04) : 573 - 574
  • [5] The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
    Khan, Omer
    Chaudary, Nauman
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 2287 - 2294
  • [6] Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex
    Swenson, Colin
    Del Parigi, Angelo
    [J]. MAYO CLINIC PROCEEDINGS, 2020, 95 (01) : 201 - 202
  • [7] In reply-Amikacin Liposome Inhalation Suspension as a Treatment Option for Refractory Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium avium Complex
    Shulha, Jennifer
    [J]. MAYO CLINIC PROCEEDINGS, 2020, 95 (01) : 202 - 202
  • [8] Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT)
    Griffith, David E.
    Eagle, Gina
    Thomson, Rachel
    Aksamit, Timothy R.
    Hasegawa, Naoki
    Morimoto, Kozo
    Addrizzo-Harris, Doreen J.
    O'Donnell, Anne E.
    Marras, Theodore K.
    Flume, Patrick A.
    Loebinger, Michael R.
    Morgan, Lucy
    Codecasa, Luigi R.
    Hill, Adam T.
    Ruoss, Stephen J.
    Yim, Jae-Joon
    Ringshausen, Felix C.
    Field, Stephen K.
    Philley, Julie V.
    Wallace, Richard J., Jr.
    van Ingen, Jakko
    Coulter, Chris
    Nezamis, James
    Winthrop, Kevin L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (12) : 1559 - 1569
  • [9] Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients
    Griffith, D. E.
    Eagle, G.
    Thomson, R. M.
    Aksamit, T. R.
    Hasegawa, N.
    Morimoto, K.
    Addrizzo-Harris, D. J.
    O'Donnell, A. E.
    Marras, T. K.
    Flume, P. A.
    Loebinger, M. R.
    Morgan, L. C.
    Castellotti, P. F.
    Hill, A. T.
    Ruoss, S. J.
    Yim, J. J.
    Ringshausen, F. C.
    Field, S. K.
    Nezamis, J.
    Winthrop, K. L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [10] Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease
    Jhun, Byung Woo
    Yang, Bumhee
    Moon, Seong Mi
    Lee, Hyun
    Park, Hye Yun
    Jeon, Kyeongman
    Kwon, O. Jung
    Ahn, Jungmin
    Moon, Il Joon
    Shin, Sung Jae
    Daley, Charles L.
    Koh, Won-Jung
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (07)
12345